RIPK1 and non-small cell lung carcinoma: Therefore, we could not exclude the possibility that RIP1 and/or RIP3 are regulated by Skp2 and responsible for cisplatin resistance in NSCLC cells, and the mechanisms underlying how Skp2 regulates RIP1 and RIP3 need to be further explored.